Home>>Piperacillin-d5

Piperacillin-d5 (Synonyms: Pipracil-d5)

Catalog No.GC40090

Piperacillin-d5 is intended for use as an internal standard for the quantification of piperacillin by GC- or LC-MS.

Products are for research use only. Not for human use. We do not sell to patients.

Piperacillin-d5 Chemical Structure

Size Price Stock Qty
500μg
$265.00
In stock
1mg
$506.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Piperacillin-d5 is intended for use as an internal standard for the quantification of piperacillin by GC- or LC-MS. Piperacillin is a broad-spectrum β-lactam antibiotic of the penicillin class. It is active against Gram-negative and Gram-positive bacteria, including Enterococcus species, E. coli, and P. mirabilis (MIC50s = 0.5-2 µg/ml) as well as gentamicin-susceptible and -resistant strains of P. aeruginosa (MIC50s = 8 and 125 µg/ml, respectively). In a mouse model of systemic infection, piperacillin is active against P. aeruginosa 46220 when used alone or in combination with tazobactam . In the same model, it is less active against P. aeruginosa 46220 DR-2, which contains constitutively active β-lactamase, when used alone than when used in combination with tazobactam (ED50s = >20 and 4.39 mg/animal, respectively). Formulations containing piperacillin in combination with tazobactam have been used in the treatment of moderate-to-severe bacterial infections.

Reviews

Review for Piperacillin-d5

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Piperacillin-d5

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.